Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alexion Seizes On New Soliris Indication, Business Development For Growth

Executive Summary

Alexion will target Soliris to about 3,000-8,000 US patients with ultra-rare generalized myasthenia gravis (gMG) following FDA approval. Meanwhile, the company has hired a new head of business development.

You may also be interested in...



Phase II Success Positions Ra For Potential Blockbuster Opportunity In Myasthenia Gravis

Ra hopes to launch a Phase III program for zilucoplan next year, with a goal of bringing an alternative therapy for MG patients into competition with Alexion’s Soliris.

Alexion Continues Pipeline Rebuilding With $400m Takeout Of Syntimmune

Alexion’s third deal this year brings privately held Syntimmune and its Phase Ib/IIa candidate for three IgG-mediated rare disorders, including warm autoimmune hemolytic anemia, for a $400m upfront price tag.

Alexion Gets Speedy Review For Soliris Successor

Switching patients from the very expensive ultra rare disorder drug to ravulizumab will be a key strategy for Alexion if the latter is approved. Recent compelling data in paroxysmal nocturnal hemoglobinuria patients suggests the long-acting C5 complement inhibitor could offer more benefit than its predecessor with more convenient dosing.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134885

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel